Other languages Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E. Other stock markets 09:00:00 17/05/2024 pm IST			5-day change	1st Jan Change
16.2 ^USD	-4.42%		-0.64%	+55.25%

17/05	Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	MT
15/05	Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	17/05
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	15/05
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	15/05
En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...	09/05
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	08/05
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	08/05
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	08/05
Sector Update: Health Care	08/05
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	08/05
Teva Pharm Q1 profit falls short of estimates, revenue gains	08/05
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	08/05
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	01/05
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	01/05
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	30/04
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	17/04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 03:11 pm IST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 03, 2023 at 12:49 am IST